The outcomes of these trials have been highly encouraging and the salient information gained from the studies is the following: HSV1716 is non-toxic when directly injected into tumours or into normal brain following tumour resection; HSV1716 replicates in glioma and melanoma; evidence of HSV1716 induced tumour necrosis in melanoma nodules has been obtained; there is no evidence of virus replication in cells other than tumour cells; the immune status of the patients with respect to HSV antibody levels pre-virus administration has little impact on the outcome of HSV1716 infection. All of these findings must be regarded as indicative of the potential of HSV1716 as an anticancer agent. Perhaps of even more importance is the finding that a number of the glioma patients with recurrent disease at the time of study entry have lived longer than would be normally expected in this disease where the average survival is 1 year from the time of initial diagnosis.
ICP34.5-HSV1716, 1 a selectively replication competent mutant of herpes simplex virus replicates in and lyses tumour cells, 2 but fails to replicate in growth arrested, terminally differentiated cells. 3 We have completed three clinical trials using HSV1716 in glioma patients 4, 5 and one trial in patients with metastatic melanoma. 6 The outcomes of these trials have been highly encouraging and the salient information gained from the studies is the following: HSV1716 is non-toxic when directly injected into tumours or into normal brain following tumour resection; HSV1716 replicates in glioma and melanoma; evidence of HSV1716 induced tumour necrosis in melanoma nodules has been obtained; there is no evidence of virus replication in cells other than tumour cells; the immune status of the patients with respect to HSV antibody levels pre-virus administration has little impact on the outcome of HSV1716 infection. All of these findings must be regarded as indicative of the potential of HSV1716 as an anticancer agent. Perhaps of even more importance is the finding that a number of the glioma patients with recurrent disease at the time of study entry have lived longer than would be normally expected in this disease where the average survival is 1 year from the time of initial diagnosis.
The first trial in patients with grade IV glioma started in October 1997 and the procedure involved virus injection into tumour and no further surgical intervention. From that study two patients are alive and stable at 4 years 4 months and 3 years 7 months. A third patient from the initial study, who had subsequent chemotherapy died at 3 years 2 months from the time of initial HSV1716 injection. This patient was tumour progression free (as assessed by MRI) for 2 years 10 months. Following tumour regrowth, her tumour was resected and she had a further dose of HSV1716 injected into tumour cavity. She lived for 4 months beyond the time of surgery.
Following surgery, tumour tissue was dissociated and cultured in order to determine permissivity for HSV1716 replication. The tumour cells (designated JF) were grown in DMEM plus 10% calf serum and split 1:2 as required. Cell division was slow. It took 12-14 days for a flask of cells to be confluent enough to split 1:2. They were confirmed as glial in origin by appearance and by positive, characteristic immunostaining for glial fibrillary acidic protein GFAP (Figure 1 ). They were also immunostained for proliferating cell nuclear antigen (PCNA). We have shown that ICP34.5 complexes with PCNA 7 and we believe that the level of PCNA determines permissivity for HSV1716 replication. It can be seen in Figure 2 that there is a high level of PCNA confined to the nuclei of the cells and the large multivacuolated appearance of the nuclei is typical of the cells which were grown from the tumour. 100% of the JF cells were positively stained for both GFAP and PCNA. At 45 days post initiation of in vitro culture, enough cells were obtained to carry out a multicycle HSV1716 growth experiment. 8 Cells were infected at a multiplicity of infection (MOI) of 0.1 p.f.u./cell with either HSV1716 or HSV 17 + , the wild-type virus from which HSV1716 was derived. One plate of cells was mock infected. Following incubation at 37°C, the samples were harvested at 0, 6, 24, 48 and 72 h after infection by scraping the cells into the medium. Virus was released by sonication and titrated on BHK cells. Parallel multicycle infections were carried out in BHK21/C13 cells which are fully permissive for HSV1716 replication and in 3T6 cells which are non-permissive for HSV1716 replication, but permissive for wild-type HSV replication. 3 The experiment had been designed to run over a 72-Gene Therapy h period, but additional monolayers had been infected. Incubation of one plate of 17 + infected cells, one plate of 1716 infected cells and the mock infected monolayer continued beyond 72 h at 37°C. Although all the cells in the HSV17 + infected plates were totally rounded up by 72 h after infection, it was clear that a proportion of cells on the HSV1716 infected plates remained viable. The growth medium on these plates was changed on a regular basis and the decanted supernatant was harvested and stored at -70°C. Supernatant medium was obtained on days 7, 10, 13, 17, 20, 24, 27, 31 and 35 after virus infection.
The HSV1716 infected JF cells continued to divide and by day 20 they had the appearance of being almost confluent. However, there were a number of individual cells and small foci which had the typical swollen cell appearance of HSV infection. The appearance of mock infected cells and infected cells at day 24 after infection are illustrated in Figure 3a and b, respectively. The low grade persistent infection remained apparent until day 30 when there was a rapid spread of infection throughout the monolayer with no remaining viable cells by day 35. The appearance of the infected cells at day 35 is shown in Figure 3c .
The titres of progeny virus can be seen in Figure 4a . As expected both HSV17
+ and HSV1716 replicated efficiently in BHK cells and their growth patterns were virtually indistinguishable: HSV17 + grown in 3T6 cells replicated to a high titre over the 72 h period, whereas HSV1716 failed to replicate. HSV17
+ replicated well in the JF cells with a thousand-fold increase in titre over the 72-h period. Although there is evidence that HSV1716 replicated, the curve is very flat and replication appears to have taken place in the first 24 h after infection and thereafter has plateaued. As a comparison it can be seen in Figure 4b and c that in two other primary glioma cells lines both HSV17
+ and HSV1716 grew to high titre. The cultures SB and LW were derived from tumour obtained at the time of surgery from two patients who subsequently had HSV1716 injected into tumour cavity. Both of these patients had no previous exposure to HSV1716.
Virus in the supernatant medium collected from both the HSV17 + and HSV1716 infected JF cells over the 35-day period was titrated on BHK cells. The titres of virus obtained are shown in Figure 5 . It can be seen that the HSV17 + titre had reached a peak at day 3. Only virus released into supernatant was titrated after that time and there was a rapid decline over the next 7 days. In the HSV1716 infections the titre of released virus declined more slowly up to day 20 when approximately 40 p.f.u. were recovered from the 35 mm plate of cells. During the next 7 days, there was obvious virus replication and by the 24th day 8.2 × 10 2 p.f.u. was obtained from the 35-mm plate of cells. This gradual rise in virus replication continued to day 31 when a total of 3.9 × 10 5 p.f.u. was obtained. By day 35 all the cells had died and the reduction in titre demonstrates that no further infectious virus was being released. No virus was obtained from mock-infected JF cells at any time.
To confirm the identity of the virus which was recovered from the JF cells at days 7 and 35, DNA was extracted and PCR analysis was carried out using primers which identify the UL42 locus of HSV 1. 9 As a control, DNA was extracted from HSV1716 infected BHK cells. A band of the expected size was obtained from both the 7 and 35 day virus samples obtained from the JF cells
Figure 3 (a) A phase contrast image of a mock infected (MI) monolayer of JF cells. (b) A HSV1716 infected monolayer of JF cells, 24 days after infection. A focus of virus infection is highlighted by an arrow. (c) A HSV1716 infected monolayer at 35 days after infection. The appearance of the cells is characteristic of a total lytic infection.
(R Mablas, personal communication). This confirmed that the isolated virus was herpes simplex virus and not any other contaminating virus.
The clinical trials carried out using HSV1716 in glioma patients have been classified as phase 1 toxicity trials and not efficacy trials. We therefore make no claims regarding the efficacy of this therapeutic approach in glioma. However, from the first trial in which HSV1716 was directly injected into tumour in patients with recurrent highgrade glioma with no further surgical intervention, three patients (trial of nine) lived considerably longer (currently up to 4 years 4 months) than would be expected with this disease, where the average survival is 1 year from diagnosis of primary tumour. The clinical Figure  4a (JF cells). At 7, 10, 13, 17, 20, 24, 27, 31 aspects of these patients is the subject of a separate manuscript in preparation (Papanastassiou et al) .
Figure 5 Up to 3 days after infection, the titre of progeny virus was calculated from harvests of cells plus supernatant medium and is shown to the left of the vertical dotted line. This is the same data as shown in
The encouraging and intriguing outcome in this small cohort of patients has led us to speculate on the mechanisms which may be responsible. Among the possible reasons for the extended life span of these patients, it has to be considered that HSV1716 infection of the tumours, plays a role. High-grade glioma is mostly made up of rapidly dividing cells, but in addition there are cells in all stages of the cell cycle with a proportion being necrotic. We know the HSV1716 replicates efficiently in rapidly dividing cells and lyses them. It also infects cells which are not dividing and transcription and translation from the virus genome takes place. 3 Although it does not replicate in neurons, it nevertheless infects neurons and establishes a latent infection.
10 HSV1716 therefore has the ability to infect cells at all stages of the cell cycle, but the outcome of infection is cell cycle dependent.
Stereotactically guided multipoint injection along one trajectory was used to infect tumour in situ. 5 Inevitably, during this process and as the infection progressed, infectious virus particles would encounter cells at different stages in the cell cycle. Virus replication and cell lysis would take place in some and in others, although infection would take place, virus replication would not. It has to be considered that HSV1716 could remain in a state of equilibrium with non-dividing cells, and only when the cell subsequently enters the replicative state does the virus have the ability to go through a full replication cycle.
In this article, we present evidence that HSV1716 has the ability to 'persist' in human glioma cells in vitro. Unsurprisingly, based on our previous work, 2 we show that HSV1716 replicates in primary human glioma cells in vitro. Infection of JF glioma cells in vitro by wild-type HSV resulted in virus replication and lysis of all infected Gene Therapy cells. Following HSV1716 infection however, although it is clear that lytic replication took place, it is also clear that a proportion of the cells did not provide an environment in which the virus could lytically replicate. By comparison, the two other primary glioma cultures infected with HSV1716, supported efficient virus replication. In JF cells, by 72 h after infection, the virus titre had peaked and there is a reduction in release of infectious virus. It was evident however both from the appearance of the cultures and from subsequent titration of supernatant medium, that HSV1716 had not cleared from the culture plates and was persisting and infectious. Not only that, but cells were continuing to divide and cell numbers were increasing. The lowest recovery of infectious virus was 20 days after infection, but by 25 days the titre had increased and continued to do so for approximately the next 10 days. It could possibly be argued that the poor infection is due to a deficit in receptors in these cells, but that is obviously not the case as HSV17
+ was able to totally destroy a monolayer of cells within 72 h. It also has to be considered that HSV1716 was moving intracellularly by cell to cell spread and was not released into the medium. However when this happens, the infected cells generally form giant multinucleated syncitia and there was no evidence of these characteristic syncitia in the cultures. We know that replication of HSV1716 is dependent on the stage in the cell cycle and we propose therefore that the persistence of HSV1716 in these primary human glioma cells results from the different stages in the cell cycle present within the population of cells in the monolayer. It is highly unlikely that this is a latent infection, but merely persistence resulting from the selectively replication competent phenotype of HSV1716. Compared with other primary glioma cells, the JF cells as a population divided slowly and it may be that this provided the ideal environment for a persistent infection to be maintained.
The JF tumour was analysed by PCR for HSV DNA immediately after tumour resection and none was obtained (R Mabbs, personal communication). The cells which were put into culture and not infected remained normal in appearance with no evidence of virus. It is highly unlikely therefore that these cells had residual 'latent' HSV1716 genomes remaining from the time of tumour inoculation in situ in 1998. The theoretical possibility cannot, however, be totally ruled out. It is well documented that superinfection with HSV in vitro can lead to reactivation of latent virus and this occurs in cells other than neurons. 11 If a proportion of the cells which were put into culture had latent HSV1716 genomes, this could render them more refractory to superinfection with HSV, but the presence of lytic virus replication in surrounding cells could be enough to trigger reactivation. As infection in vitro was with HSV1716, the possibility of distinguishing reactivated virus from infecting genomes did not arise.
In conclusion, we provide evidence that HSV1716 can 'persist' in glioma cells at least in vitro and we suggest that this gives credence to the possibility that in tumours in vivo a similar phenomenon may take place. If this were the case, then it argues that HSV1716 could have the potential to kill tumour cells over a prolonged period of time.
